Novo Holdings A/S’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Novo Holdings A/S’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-676,379	Closed	-$1.92M	–	42
2023 Q3	$1.92M	Sell	676,379 -2,986,257	-82%	-$8.23M	0.14%	37
2023 Q2	$9.52M	Sell	3,662,636 -277,777	-7%	-$582K	0.74%	31
2023 Q1	$113M	Hold	3,940,413	–	–	7.45%	3
2022 Q4	$6.5M	Hold	3,940,413	–	–	0.41%	41
2022 Q3	$7.57M	Sell	3,940,413 -900,000	-19%	-$2.35M	0.36%	42
2022 Q2	$14.5M	Hold	4,840,413	–	–	0.71%	26
2022 Q1	$18.2M	Hold	4,840,413	–	–	0.96%	18
2021 Q4	$55M	Hold	4,840,413	–	–	2.61%	9
2021 Q3	$84.9M	Hold	4,840,413	–	–	4.39%	7
2021 Q2	$104M	Buy	+4,840,413	New	+$90.7M	4.59%	7

Other funds holding CYT

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return

Novo Holdings A/S's CYT Position: Q4 2023 in Review

Novo Holdings A/S sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q4 2023, closing a stake of 676,379 shares — an estimated $1.92M sold.

Novo Holdings A/S first reported a position in CYT in Q2 2021 and held it in 10 quarters. The position peaked at $113M in Q1 2023. 38 funds tracked by Wall St. Rank hold CYT as of Q4 2023.

Novo Holdings A/S reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Novo Holdings A/S sold 676,379 Cyteir Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.92M.
Novo Holdings A/S first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
Novo Holdings A/S's Cyteir Therapeutics, Inc. Common Stock position peaked at $113M in Q1 2023.
38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Novo Holdings A/S's 13F filing for Q4 2023, filed 14 Feb 2024.